Glucagon-Like Peptide-1 (Glp-1) Analogs Market will generate new growth opportunities 2022-2028 | Novo Nordisk, Eli-Lilly and Company

Glucagon-Like Peptide-1(Glp-1) analogs and their derivatives are an important part of diabetes management. These analogs can help to control the blood glucose level more effectively. The term ‘glucagon-type’ is a synonym for glucagon which is a naturally occurring hormone with multiple physiological functions. The glucagon analogs stimulate the pancreas to secrete the hormone. Glucagon-Like Peptide-1 analogs have similar effects as the natural hormone in humans.

LIMITED TIME OFFER – Hurry Up!!!
Buy Now To Avail Flat 30% Off

Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/1252

Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market: Drivers

High prevalence of diabetes is expected to propel growth of the global glucagon-like peptide-1 (glp-1) analogs market over the forecast period. For instance, according to the National Diabetes and Diabetic Retinopathy Survey report published in October 2019, the prevalence of diabetes in India was 11.8% during 2015-2019 and the prevalence of known diabetes cases was 8.0% and new diabetes cases was 3.8% during the period.

Moreover, approval and launch of new products is expected to propel growth of the global glucagon-like peptide-1 (glp-1) analogs market. For instance, in October 2017, Novo Nordisk received FDA approval for once-a-week GLP-1 analog semaglutide.

Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market: Opportunities

Patent expiry is expected to offer lucrative growth opportunities for players in the global glucagon-like peptide-1 (glp-1) analogs market. Exenatide is the first GLP-1 analog approved in 2005, marketed by AstraZeneca under brand names Byetta and Byedureon Bcise. Its patent expired in October 2017.

Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market: Restraints

Discontinuation of brands is expected to hinder growth of the global glucagon-like peptide-1 (glp-1) analogs market. For instance, GSK announced to discontinue the global sale of albiglutide brand Tanzeum, Eperzan from July 2018 due to low profits.

Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/1252

Discontinuation of clinical development is also expected to hinder growth of the global glucagon-like peptide-1 (glp-1) analogs market. For instance, in 2016, Roche decided to halt clinical development of Taspoglutide, a molecule targeting once a week dosing as against daily dosing regimen of other GLP-1 analogs, due to high gastrointestinal side effects and hypersensitivity reactions.

High cost of products is expected to hinder growth of the global glucagon-like peptide-1 (glp-1) analogs market. GLP-1 analogs are relatively expensive (US$ 492 for 30-day therapy) as compared to conventional type-2 diabetes medications (US$ 5-9 for 30-day therapy).

Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market: Competitive Landscape

Major players operating in the global glucagon-like peptide-1 analogs market include, AstraZeneca plc, Eli Lilly and Company, F., Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novo Nordisk, and Sanofi.

Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market: Segmentation

On the basis of drug:

• Exenatide
• Liraglutide
• Lixisenatide
• Dulaglutide
• Semaglutide
• Albiglutide

On the basis of distribution channel:

• Retail Pharmacy
• Hospital pharmacy

Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/1252

Reasons to Purchase This Report

• Current and future of Glucagon-Like Peptide-1 (Glp-1) Analogs Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Glucagon-Like Peptide-1 (Glp-1) Analogs Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Glucagon-Like Peptide-1 (Glp-1) Analogs Industry Impact

Chapter 2 Global Glucagon-Like Peptide-1 (Glp-1) Analogs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Glucagon-Like Peptide-1 (Glp-1) Analogs (Volume and Value) by Type
2.3 Global Glucagon-Like Peptide-1 (Glp-1) Analogs (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Glucagon-Like Peptide-1 (Glp-1) Analogs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 6 East Asia Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 7 Europe Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 8 South Asia Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 9 Southeast Asia Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 10 Middle East Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 11 Africa Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 12 Oceania Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 13 South America Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 14 Company Profiles and Key Figures in Glucagon-Like Peptide-1 (Glp-1) Analogs Business
Chapter 15 Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology